In the present study, we assessed the clinical effect of recombinant human granulocyte-macrophage colonystimulating factor (rhGM-CSF) in the treatment of refractory, grade III-IV hemorrhagic cystitis (HC) in six patients who underwent bone marrow transplantation (BMT). These were four males and two females, aged 24-40 years (median age 30.5 years). All received allogeneic BMT from HLA-identical siblings after preparation with busulfan-cyclophosphamide. HC was evident 24.5 days (range 15-33 days) after BMT. Median duration of HC before treatment was 5 days (range 4-9 days). Treatment consisted of intravesical instillation of rhGM-CSF (400 g) for 3 consecutive days. A complete response was observed in three patients, the other three showed a partial response. Median time to achieve response was 36 h (range 0.2-72 h). Hematuria was controlled after the first (two patients), second (two patients) or third (two patients) dose of intravesical rhGM-CSF. Patients were discharged from the hospital 10.5 days (range 3-41 days) after treatment. All patients have been followed for up to 10 months and none have required further treatment. No systemic or bladder side-effects have been observed. Although our results indicate that intravesical instillation of rhGM-CSF is effective in the treatment of HC, a phase II clinical trial, including a larger series of patients, is needed.
Hemorrhagic cystitis (HC) is a well-recognized and potentially fatal complication commonly observed in patients who receive high-dose cyclophosphamide (Cy). The incidence in BMT patients is 10-20%. [1] [2] [3] Acrolein, a metabolite of Cy, has been implicated as a causative agent. 4 HC after high-dose Cy is prevented by bladder irrigation, hyperhydration 5 and sulfhydryl-containing compounds such as 2-mercapto-ethane (mesna), 6 that inactivate acrolein in the urine. Other known causes of HC include exposure to busulfan, radiation, GVHD and viruses including adenovirus, 7 polyomavirus 8 and cytomegalovirus. HC can be treated by performing hyperhydration, intraCorrespondence: Dr J Vela-Ojeda, Apartado postal 14-878, código postal 07001, México, DF México Received 4 October 1998; accepted 20 July 1999 vesical instillation of prostaglandins, 9 ,10 silver nitrate, 11 formalin 12 and occasionally by cystostomy, bladder packing and cystectomy. 13 Granulocyte-macrophage colony-stimulating factor is one of the main regulators of myeloid cell production, both in vivo and in vitro. Recently, recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) has been used in the treatment of certain inflammatory and ulcerative conditions such as BMT-associated mucositis, 14 and leg ulcers. 15 In the present study, we describe our experience with intravesical rhGM-CSF in the treatment of late-onset HC refractory to conventional therapy. To our knowledge, this is the first report on the use of local rhGM-CSF in the treatment of HC after BMT.
Patients and methods
From February 1997 to July 1998, we treated six patients with late onset HC. We used our own grading system for HC: grade 0 = no HC, grade I = microscopic hematuria, grade II = macroscopic hematuria, grade III = macroscopic hematuria with clots and grade IV = macroscopic hematuria requiring red blood cell transfusion or instrumentation. The criteria for participation in the study included grade III or IV HC resistant to forced diuresis, continuous bladder irrigation with normal saline and i.v. mesna. HC was defined as an episode of symptomatic (burning, frequency or dysuria) macroscopic hematuria in the absence of bacterial cystitis or other clinical conditions, such as intravascular coagulation or sepsis. We defined late onset HC as the occurrence of HC after 10 days of administration of Cy. Informed consent for the use of intravesical rhGM-CSF was obtained in accordance with an approved institutional review board in our hospital.
Chemotherapy regimen
All patients underwent allogeneic HLA-identical sibling BMT after preparation with BuCy: busulfan 4 mg/kg/day p.o. in divided doses, daily for 4 days (total of 16 mg/kg) followed by cyclophosphamide 60 mg/kg once daily i.v. on days 1 and 2 (total dose 120 mg/kg). All patients received prophylactic mesna as an intermittent i.v. bolus every 3 h (total of 60% of Cy dose). We used acyclovir 500 mg/m 2 i.v. every 8 h as a prophylaxis for CMV disease.
Hydration, bladder irrigation and treatment
Prior to the initiation of the first Cy dose, i.v. hyperhydration was started with normal saline, 5 g dextrose and 8 mEq KCl/l (250 ml/h). Patients with HC were treated with continuous bladder irrigation of normal saline 1000 ml/h and i.v. mesna 15 mg/kg every 4 h for at least 3 days. Based on good results with the use of rhGM-CSF in mucositis after BMT 14 and as a desperate measure because of our negative experience with late onset HC (prolongation of hospitalization, high transfusions requirements and even death) we treated all patients with intravesical instillation of rhGM-CSF (leucomax; Novartis/Schering-Plough, Mexico DF, Mexico) 400 g diluted in 200 ml normal saline allowed to rest for 60-120 min. After treatment, the catheter was unclamped and continuous bladder irrigation with normal saline was continued. Treatment was given for 3 days (total bladder exposure to GM-CSF of 6 h). We used empirically the same GM-CSF dose as in BMT mucositis.
Urine cytology and urine cultures for virus were not routinely performed.
Criteria for response
Complete response (CR): if hematuria and symptoms ceased after 1-3 days of treatment and no recurrence in the next week after treatment. Partial response (PR): diminution of hematuria to the point of not requiring transfusion or presence of microscopic hematuria with no symptoms. Failure: no response to treatment or reappearance of hematuria and symptoms immediately after discontinuation of treatment. Recurrence: start of macroscopic hematuria у1 week after achieving a CR. Table 1 . Median age was 30.5 years (range 24-40 years). Patients included four males and two females, four had CML, one had AML and one had ALL. Two of six patients had acute GVHD at the time of HC onset. HC at presentation was grade III in two patients and grade IV in four. Median duration of HC before start of treatment was 5 days (range 4- 9 days). The median time of presentation of HC was 24.5 days (range 15-33 days) after BMT. Three patients achieved a complete response and three a partial response. Median time to achieve response was 36 h (range 0.2-72 h). In one patient, macroscopic hematuria and clots disappeared 15 min after treatment with rhGM-CSF and in another patient with partial response who recurred 10 days after treatment, a complete response was achieved with a second treatment of rhGM-CSF at 800 g for 3 days. In all patients hematuria was controlled after 3 days of treatment (two patients within the first dose, two within the second and two within the third dose of rhGM-CSF). In patients achieving PR, a completely clear urine (no macroscopic neither microscopic hematuria) was observed after a median of 8 days (range 5-13 days). Median time of rhGM-CSF exposition to bladder was 92.5 min (range 15-120 min). Cystoscopy was performed in two patients before and after treatment. Before therapy, in both cases inflammation, erythema, ulceration and reduced bladder capacity was present. Biopsy specimens showed atypical epithelial cells consistent with a chemotherapy effect in one and viral inclusion bodies in the other. The latter patient was treated with gancyclovir 5 mg/kg i.v. for 14 days. Cystoscopy after rhGM-CSF treatment showed resolution of inflammation and ulcers in both patients. The patients were discharged from the hospital a median of 10.5 days after start of treatment (range 3-41 days). No patient required further treatment. Median follow-up (time after treatment with rhGM-CSF) was 10 months (range 2-21 months). Two patients died 2 and 5 months after treatment due to grade IV aGVHD and chronic extensive GVHD, respectively and HC was not present at the time of death. Four patients are alive without HC.
Results

Patient characteristics and results are shown in
The only patient who required RBC (2 units) and platelet (3 units) transfusions was given a second treatment of rhGM-CSF (patient No. 2) and was discharged from hospital later (41 days) because of grade IV aGVHD.
We did not observe systemic or bladder side-effects with the use of intravesical rhGM-CSF.
Discussion
HC is an important cause of morbidity and prolonged hospitalization in a significant proportion of patients after BMT. Despite the administration of mesna and the use of hyperhydration and bladder irrigation, HC is a major complication after Cy-containing preparative regimens and a direct cause of death. 16 A higher frequency of HC is associated with allogeneic BMT, 17 the presence of GVHD, 18 history of busulfan use, 19 and pelvic irradiation. 16 As a rule, HC follows the administration of Cy and transient HC of early onset is thought to be due to a direct toxic effect of Cy-metabolites on bladder mucosa. The cause of long-lasting HC of late onset has remained obscure. Some viruses have been isolated from serum and urine in these patients, mainly adenovirus, 7, 20, 21 polyomavirus, 8 CMV 22 and influenza. 23 Some investigators have reported the utility of ribavirin in adenovirus-related HC 24 and others observed a reduction of adenovirus and polyomavirus excretion in the urine of BMT recipients after treatment with vidarabine, 25, 26 achieving CR in some of them. In our study, a viral cause was demonstrated in one patient who responded to rhGM-CSF treatment (urine viral cultures were not performed routinely).
Treatment of late onset refractory HC is a great challenge to all health care professionals involved with BMT patients. Intravesical instillation of 1% alum (aluminum ammonium phosphate or aluminum potassium sulfate) is reported to have a variable rate of succes: CR of 50-100% and recurrence rate of 17.9%. 27, 28 Some side-effects can be observed such as allergic reaction, central nervous system disturbance, metabolic acidosis and coagulopathy. Intravesical 1% silver nitrate is another choice but the risk of ureteral obstruction from silver salts makes it a second alternative treatment. 29 Intravesical formalin therapy has been used to control intractable hematuria due to radiotherapy in patients with bladder carcinoma. 30 In HC, CR is achieved using this substance within 48 h in 83%, 78% and 71% of the patients, depending on the formalin concentration used (10%, 5% and 1%, respectively). 12 Formalin can cause severe suprapubic pain requiring regional or general anesthesia. Other side-effects are vesicoureteral reflux, bladder and ureteral fibrosis, hydronephrosis, papillary necrosis and bladder rupture with intraperitoneal extravasation of formalin. Intravesical instillation of various types of prostaglandins (E1, E2 and F2) have been utilized with some success: CR 50% and PR 44% , but bladder spasms ocurred in 95-100% of the cases. 31, 32 Another local treatment is phenol, however this procedure requires general or regional anesthesia and can produce ureteral stenosis. 33 Surgical procedures to control HC in cases of uncontrollable life-threatening hemorrhage include: percutaneous nephrostomy, open cystostomy, bladder packing, hydrostatic tamponade of the bladder, 34 selective embolization of branches of the internal iliac arteries and cystectomy. 16 Patients treated with hyperbaric oxygen 35, 36 (sessions of 100% oxygen inhalation at 2-3 bar for 60-90 min/day) achieved 92% of responses with no adverse effects, but a hyperbaric chamber is required and is a prolonged procedure (20-30 days) . More recently, the use of neodymium YAG laser was reported to stop gross hematuria in three of three pediatric patients with HC. 37 Epsilon-aminocaproic acid, an inhibitor of fibrinolysis, may be administered orally or parenterally for the treatment of HC, 38 but accelerated clot formation and the potential for hypotension and acute renal failure during its administration are serious disadvantages. All of these therapeutic options have advantages and limitations and a treatment is required that is easily applied and has few or no sideeffects.
GM-CSF has pleiotropic activity that influences not only proliferation and differentiation of hematopoietic progenitor cells but also regulates other cells involved in acute and chronic inflammation (neutrophils, monocytes, lymphocytes, keratinocytes, langerhans and endothelial cells) as well as in the immune response. This factor has a potential tissue healing effect, as shown by some reports of its use in skin lessions of leprosy, Kaposi's sarcoma, 39 skin grafts, 40 drug-induced mucositis, 14 chronic leg ulcers, 41 healing cut, burn-wounds, 42 and pressure ulcers. 43 To our knowledge, this is the first report on the use of rhGM-CSF for the treatment of HC. While the series of patients included in this study is small, the results are very encouraging since HC was reversed quickly and clot formation ceased. We achieved a CR in three patients and PR in the other three. All were discharged from hospital a few days after treatment. We also observed a low frequency of RBC and platelets transfusion requirements. All of this contributed to reduce the costs of BMT. Sencer et al 44 reported an average duration of treatment of 37 days in patients with HC and an average delay in hospital discharge of 15 days. Yang et al 17 observed a higher hospitalization cost in patients with HC vs those with no HC.
In this regard, our results seem to be of significant clinical relevance. Intravesical rhGM-CSF seems to be useful in the treatment of late onset HC, however, a larger phase II trial of the use of rhGM-CSF in HC is needed.
